Dapsone therapy for hidradenitis suppurativa

Murray, Gregg R.; Hollywood, Aoife; Kirby, Brian; Hughes, Rosalind

doi:10.1111/bjd.19136

Cited by 14 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some patients responded to a lower dose while others required a relatively higher dose. The studies by Murray et al [ 24 ] and Lopez-Llunell et al [ 35 ] did not show any significant treatment response with dapsone. One study reported the need for maintenance dosage therapy to sustain positive patient outcomes [ 31 ].…”

Section: Discussionmentioning

confidence: 95%

“…The remaining 6 (31.6%) patients had no change in their health status. Adverse events were reported in 4 cases Nausea Murray et al (2020) [ 24 ] 25 patients (18 females; 7 males) Median age: 42 years Uncontrolled retrospective study 4 Hurley I: 28% Hurley II: 60% Hurley III: 12% Dapsone 50–200 mg/day for 1–3 months Sixteen (64%) patients had clinically subjective improvement while no improvement was seen in 8 (32%) patients. The use of dapsone was discontinued in 2 patients due to adverse events Anemia Lopez-Llunell et al (2021) [ 35 ] 56 patients (19 females; 37 males) Median age: 33 years Uncontrolled retrospective single-center study 4 Hurley I: 53.6% Hurley II: 23.2% Hurley III: 23.2% Dapsone [+ isotretinoin or acitretin in 4 cases] 50–150 mg/day for 3–14 months Thirty-five (62.5%) patients had clinically significant improvement while others did not show such response.…”

Section: Resultsmentioning

confidence: 99%

“…Based on the results of this systematic review, dapsone was relatively well tolerated when used in the management of HS. The incidence rate of adverse events was 25.1%, with nausea and anemia being the most commonly reported adverse events [ 24 , 32 , 34 ]. Furthermore, the effects of the adverse events on treatment outcomes were not significant in most cases.…”

Section: Discussionmentioning

confidence: 99%

“…It is against this backdrop that researchers and physicians have been looking for more effective antimicrobial agents, and dapsone appears to offer some promise in this regard. It should be noted that the main objective of treatment with dapsone is to improve the quality of life together with reduction of pain, lesion formation and flare count [ 24 ].…”

Section: Treatment Of Hsmentioning

confidence: 99%

See 3 more Smart Citations

Dapsone in Hidradenitis Suppurativa: A Systematic Review

Rabindranathnambi

Jeevankumar²

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent disease, usually presenting after puberty with inflammatory lesions that mainly affect the apocrine gland-bearing areas of the body, most commonly the axillary, inguinal and anogenital regions. The treatment of HS is associated with certain challenges due to intrinsic resistance to various treatments and the presence of comorbidities and complications. The antibiotic dapsone is an established treatment for HS, but the current evidence base is limited. The aim of this review is to systematically review the literature on the efficacy of dapsone in the treatment of HS. Methods: The Cochrane, PubMed and CINAHL databases were searched for relevant articles to be included in the systematic review.Results: A total of seven studies, with a cumulative patient population of 135 patients, were included. Of these 135 patients, 62.2% demonstrated various degrees of improvement following treatment. However, as only three of the seven studies used dapsone monotherapy it is difficult to assess the effectiveness of dapsone because the benefits observed may be due to concurrently administered treatment. Conclusion: Overall, the quality of evidence supporting the use of dapsone is weak. However, it is a well established treatment recommended in current, various national guidelines. There is a crucial need for well-designed randomized controlled trials to support its usage.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Treatment Of Hsmentioning

confidence: 99%

See 2 more Smart Citations

Dapsone in Hidradenitis Suppurativa: A Systematic Review

Rabindranathnambi

Jeevankumar²

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…34,79 84 In this context, dapsone therapy, which targets neutrophil-mediated inflammation, may lead to clinical improvement in HS patients. 85 While a role for other granulocyte populations in HS pathogenesis was initially dismissed, this picture has changed recently. 86 For example, mast cells appear to be elevated in HS lesions and pruritus, often associated with histamine release, is a common but under-reported feature of this disease.…”

Section: Hs Inflammation Propagators: Neutrophils and Other Granulocytesmentioning

confidence: 99%

Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction?

Johnston

Kirby

Tobin

2021

Experimental Dermatology

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease affecting the axillae, perineum and inframammary regions, among other body sites. Accumulating evidence indicates a hair follicle (HF) focus to this disease, as it is characterized by an early occlusion, followed by rupture of the HF and more generalized skin inflammation. 1 HS is part of the follicular occlusion tetrad of disorders (HS, acne conglobata, dissecting cellulitis of the scalp and pilonidal sinus).It results in painful local nodules and abscesses that can develop into pus-filled malodorous sinus tracts, also known as tunnels, that may result in extensive scarring. 2,3 In addition to cutaneous inflammation, patients with moderate-to-severe HS have evidence of systemic inflammation, as measured by C-reactive protein (CRP) and highsensitivity CRP. 1,4-8 Thus, it is unsurprising that HS is associated with significant psychosocial morbidity and profoundly impaired patient quality of life, when compared to other inflammatory skin diseases such as psoriasis. [9][10][11][12] Aside from the obvious pain and discomfort of HS lesions, patients commonly experience mood disorders (eg depression), altered body image, stigmatization, social isolation and sexual dysfunction. 9,[12][13][14][15][16] Approximately 35% of HS cases in northwestern European cohorts display a positive family history which suggests a genetic component. 17 This is less in some Asian populations at approximately 5% of patients. 18,19 Environmental factors,

show abstract

Hidradenitis Suppurativa

Ingram,

van der Zee,

Jemec

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

Hidradenitis suppurativa is a chronic, inflammatory, follicular disease that usually presents at or after puberty. Painful, deep‐seated inflamed skin lesions occur in apocrine gland‐bearing areas, most commonly the axillary, inguinal and ano‐genital regions. The skin lesions may discharge blood‐stained pus and leave scarring, including skin tunnel formation. Prevalence is estimated at 1% and, in Europe, young adult women are particularly affected. There is a link with smoking, obesity, depression and cardiovascular disease. Baseline disease severity is typically measured by Hurley staging and response to treatment by pain numerical rating scales, quality of life, a lesion count and global assessment. Medical treatment includes antibiotics, anti‐androgens, and antitumour necrosis factor  therapies, integrated with surgical options such as deroofing and wide excision.

show abstract

Dapsone therapy for hidradenitis suppurativa

Cited by 14 publications

References 8 publications

Dapsone in Hidradenitis Suppurativa: A Systematic Review

Dapsone in Hidradenitis Suppurativa: A Systematic Review

Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction?

Hidradenitis Suppurativa

Contact Info

Product

Resources

About